| 3 |
平育敏，白世祥，王福顺，等．食管癌和贲门癌20000例外科治疗经验[M]．中国首届国际食管癌学术会议暨第七届全国食管癌学术会议，2005：167-171.
|
| 4 |
邵令方，陈宇航，李冰，等．食管癌和贲门癌的外科治疗15707例总结——附河南省食管癌的防治研究概况[M]．中国首届国际食管癌学术会议暨第七届全国食管癌学术会议．2005：40-46.
|
| 5 |
Walsh TN, Noonan N, Hollywood D，et al．A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma[J]．N Engl J Med，1996，335(7): 462-467.
|
| 6 |
Bosset JF, Gignoux M, Triboulet JP，et al．Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus[J]．N Engl J Med，1997，337(3): 161-167.
|
| 7 |
Burmeister BH, Smithers BM, Gebski V，et al．Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus：a randomised controlled phase III trial[J]．Lancet Oncol，2005，6(9): 659-668.
|
| 8 |
Le Prise E, Etienne PL, Meunier B，et al．A randomized study of chemotherapy，radiation therapy，and surgery versus surgery for localized squamous cell carcinoma of the esophagus[J]．Cancer，1994，73(7): 1779-1784.
|
| 9 |
Nygaard K, Hagen S, Hansen HS，et al．Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma：a randomized，multicenter study of pre-operative radiotherapy and chemotherapy．The second Scandinavian trial in esophageal cancer[J]．World J Surg，1992，16(6): 1104-1109.
|
| 10 |
Urba SG, Orringer MB, Turrisi A，et al．Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma[J]．J Clin Oncol，2001，19(2): 305-313.
|
| 11 |
杨弘，傅剑华，胡祎，等．术前放化疗并手术治疗局部晚期食管癌[J]．中华医学杂志，2008，88(45): 3182-3185.
|
| 12 |
Yang H, Liu H, Chen Y，et al．Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus （NEOCRTEC5010）：a phase III multicenter，randomized，open-label clinical trial[J]．J Clin Oncol，2018，36(27): 2796-2803.
|
| 13 |
Lerut T．Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus：the （NEOCRTEC5010） trial—a timely and welcome clinical trial from the Far East[J]．J Thorac Dis，2018，10(Suppl 33): S4162-S4164.
|
| 14 |
李进，秦叔逵，马军，等．中国临床肿瘤学年度研究进展2018 [M]．北京：人民卫生出版社.
|
| 15 |
National Comprehensive Cancer Network．Esophageal and esophagogastric junction cancers （Version 2.2019）．Accessed 29 May，2019．
URL
|
| 16 |
中国临床肿瘤学会指南工作委员会．食管癌诊疗指南（2020版）[M]．北京：人民卫生出版社，2020.
|
| 17 |
Zhan M, Zheng H, Yang Y，et al．Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial[J]．Radiother Oncol，2019，141: 27-32.
|
| 18 |
van Hagen P, Hulshof M, Van Lanschot J，et al．Preoperative chemoradiotherapy for esophageal or junctional cancer[J]．N Engl J Med，2012，366(22): 2074-2084.
|
| 19 |
Shapiro J, Van Lanschot JJB, Hulshof MC，et al．Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer （CROSS）：long-term results of a randomised controlled trial[J]．Lancet Oncol，2015，16(9): 1090-1098.
|
| 1 |
Jemal A, Bray F, Center MM，et al．Global cancer statistics[J]．CA Cancer J Clin，2011，61(2): 69-90.
|
| 2 |
Chen W, Zheng R, Baade PD，et al．Cancer statistics in China，2015[J]．CA Cancer J Clin，2016，66(2): 115-132.
|
| 20 |
Robb WB, Messager M, Dahan L，et al．Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone[J]．Br J Surg，2016，103(1): 117-125.
|
| 21 |
Oppedijk V, Van Der Gaast A, Van Lanschot JJ，et al．Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials[J]．J Clin Oncol，2014，32(5): 385-391.
|
| 22 |
Sudo K, Taketa T, Correa AM，et al．Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies[J]．J Clin Oncol，2013，31(34): 4306-4310.
|
| 23 |
Xi M, Hallemeier CL, Merrell KW，et al．Recurrence risk stratification after preoperative chemoradiation of esophageal adenocarcinoma[J]．Ann Surg，2018，268(2): 289-295.
|
| 24 |
Dorth JA, Pura JA, Palta M，et al．Patterns of recurrence after trimodality therapy for esophageal cancer[J]．Cancer，2014，120(14): 2099-2105.
|
| 25 |
Barbetta A, Sihag S, Nobel T，et al．Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery[J]．J Thora Cardiovasc Surg，2019，157(3): 1249-1259.
|
| 26 |
Liu S, Wen J, Yang H，et al．Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma：results from the multicenter phase III trial NEOCRTEC5010[J]．Eur J Cancer，2020，138: 113-121.
|
| 27 |
Mariette C, Piessen G, Briez N，et al．The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent[J]．Ann Surg，2008，247(2): 365-371.
|
| 28 |
Rice TW, Chen LQ, Hofstetter WL，et al．Worldwide esophageal cancer collaboration：pathologic staging data[J]．Dis Esophagus，2016，29(7): 724-733.
|
| 29 |
Rice TW, Lerut T, Orringer M，et al．Worldwide Esophageal Cancer Collaboration：neoadjuvant pathologic staging data[J]．Dis Esophagus，2016，29(7): 715-723.
|
| 30 |
Leng X, He W, Yang H，et al．Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus：From the Results of NEOCRTEC5010，a Randomized Multicenter Study[J]．Ann Surg，2019，[Epub ahead of print].
|
| 31 |
Wen J, Yang H, Liu MZ，et al．Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy[J]．Ann Oncol，2014，25(9): 1769-1774.
|
| 32 |
Wen J, Luo K, Liu H，et al．MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy[J]．Ann Surg，2016，263(5): 942-948.
|
| 33 |
Liu M, Hu Y, Zhang M-F，et al．MMP1 promotes tumor growth and metastasis in esophageal squamous cell carcinoma[J]．Cancer Lett，2016，377(1): 97-104.
|
| 34 |
Wen J, Hu Y, Liu Q，et al．miR-424 coordinates multilayered regulation of cell cycle progression to promote esophageal squamous cell carcinoma cell proliferation[J]．EBioMedicine，2018，37: 110-124.
|
| 35 |
Medical Research Council Oesophageal Cancer Working Group．Surgical resection with or without preoperative chemotherapy in oesophageal cancer：a randomised controlled trial[J]．Lancet，2002，359(9319): 1727-1733.
|
| 36 |
Allum WH, Stenning SP, Bancewicz J，et al．Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer[J]．J Clin Oncol，2009，27(30): 5062-5067.
|
| 37 |
Samson P, Robinson C, Bradley J，et al．Neoadjuvant chemotherapy versus chemoradiation prior to esophagectomy：impact on rate of complete pathologic response and survival in esophageal cancer patients[J]．J Thorac Oncol，2016，11(12): 2227-2237.
|
| 38 |
Goense L, Van Der Sluis PC, Van Rossum PS，et al．Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma：A propensity score-matched analysis comparing toxicity，pathologic outcome，and survival[J]．J Surg Oncol，2017，115(7): 812-820.
|
| 39 |
Burmeister BH, Thomas JM, Burmeister EA，et al．Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial[J]．EJC，2011，47(3): 354-360.
|
| 40 |
Klevebro F, Johnsen G, Johnson E，et al．Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction：a randomized clinical trial of neoadjuvant chemotherapy vs．neoadjuvant chemoradiation[J]．EJC，2015，41(7): 920-926.
|
| 41 |
Stahl M, Walz MK, Stuschke M，et al．Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]．J Clin Oncol，2009，27(6): 851-856.
|
| 42 |
Nakamura K, Kato K, Igaki H，et al．Three-arm phase III trial comparing cisplatin plus 5-FU （CF） versus docetaxel，cisplatin plus 5-FU （DCF） versus radiotherapy with CF （CF-RT） as preoperative therapy for locally advanced esophageal cancer （JCOG1109，NExT study）[J]．Jpn J Clin Oncol，2013，43(7): 752-755.
|
| 43 |
Li F, Ding N, Zhao Y，et al．The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis[J]．Int J Surg，2018，60: 88-100.
|
| 44 |
Stiles BM, Kamel MK, Harrison SW，et al．Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology[J]．Ann Thorac Surg，2019，107(1): 187-193.
|
| 45 |
Noordman BJ, Spaander MC, Valkema R，et al．Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer （preSANO）：a prospective multicentre，diagnostic cohort study[J]．Lancet Oncol，2018，19(7): 965-974.
|
| 46 |
Noordman BJ, Wijnhoven BP, Lagarde SM，et al．Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer：a stepped-wedge cluster randomised trial[J]．BMC cancer，2018，18(1): 142-142.
|
| 47 |
Kojima T, Muro K, Francois E，et al．Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer：Phase III KEYNOTE-181 study[J]．J Clin Oncol，2019，37(4_suppl): 2.
|
| 48 |
Kato K, Cho BC, Takahashi M，et al．Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy （ATTRACTION-3）：a multicentre，randomised，open-label，phase 3 trial[J]．Lancet Oncol，2019，20(11): 1506-1517.
|
| 49 |
Huang J, Xu J, Chen Y，et al．Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma （ESCORT）：a multicentre，randomised，open-label，phase 3 study[J]．Lancet Oncol，2020，21(6): 832-842.
|
| 50 |
Hong MH, Kim H, Park SY，et al．A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma （ESCC）[J]．J Clin Oncol，2019，37(15_suppl): 4027-4027.
|
| 51 |
Ende TVD, Clercq NCD, Henegouwen MIVB，et al．A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma：The PERFECT trial[J]．J Clin Oncol，2019，37(15_suppl): 4045-4045.
|